Waldenstrom Macroglobulinemia clinical trials at UC Irvine

• A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies

  open to eligible people ages 18 years and up

  This is a first-in-human Phase 1a/1b multicenter, open-label oncology study designed to evaluate the safety and anti-cancer activity of NX-2127 in patients with advanced B-cell malignancies.

  Orange, California and other locations

Last updated: August 5, 2021